Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
Intrinsic Value
Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, levera... [ Read More ]
The intrinsic value of one
IRWD
stock under the Base Case scenario is
12.89
USD.
Compared to the current market price of 8.08 USD,
Ironwood Pharmaceuticals Inc
is
Undervalued by 37%.
Ironwood Pharmaceuticals Inc's market capitalization is 1.3B USD.
IRWD stock price is 8.08 USD.
IRWD stock price (8.08 USD) is 37% less than its Intrinsic Value (12.89 USD).
IRWD stock price (8.08 USD) is 41% less than its Relative Value (13.81 USD). Open Relative Valuation
IRWD has upside potential of 127% compared to the average analyst price target.
Open Wall St Estimates
IRWD's Revenue has grown by 8% over the past 12 months.
IRWD's Revenue has been growing by 4% per year for the last 3 years.
IRWD's Revenue is forecast to grow at a rate of 8% per year over the next 3 years.
IRWD has negative Net Income for the last twelve months.
IRWD has negative Free Cash Flow for the last twelve months.
IRWD's short-term liabilties (276m USD) exceed its short-term assets (233m USD).
IRWD's ROE (Return on Equity) has significantly decreased in the last 3 years from 739% to -655%.
IRWD's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 112% to 45%.
IRWD earns more than enough operating income (168m USD) to safely cover interest payments on its debt (14m USD).
IRWD's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 45%.
IRWD has positive Operating Income for the last twelve months.
IRWD's ROE (Return on Equity) for the past 12 months is negative and is equal to -655%.
IRWD's long-term liabilties (817m USD) exceed its long-term assets (471m USD).
IRWD has positive Net Debt. This means that the company has more debt (498m USD) than cash and short-term investments (92m USD).
IRWD has negative three-year average ROE (Return on Equity): -112%. The company is not efficient at transforming stockholders' equity into net income.
IRWD has very high three-year average ROIC (Return on Invested Capital): 93%. The company is very efficient at using invested capital to generate operating income.
IRWD's D/E (Debt to Equity) is very low and is equal to -1.44.
IRWD's Altman Z-Score is very low and is equal to -1.96.
Valuation Backtest
Ironwood Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
IRWD
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ironwood Pharmaceuticals Inc
Balance Sheet Decomposition
Ironwood Pharmaceuticals Inc
| Current Assets | 233.3m |
| Cash & Short-Term Investments | 92.2m |
| Receivables | 129.1m |
| Other Current Assets | 12m |
| Non-Current Assets | 237.8m |
| PP&E | 18.2m |
| Intangibles | 3.7m |
| Other Non-Current Assets | 215.9m |
| Current Liabilities | 276.1m |
| Accounts Payable | 7.8m |
| Accrued Liabilities | 67.5m |
| Other Current Liabilities | 200.8m |
| Non-Current Liabilities | 541.3m |
| Long-Term Debt | 498.3m |
| Other Non-Current Liabilities | 43m |
Earnings Waterfall
Ironwood Pharmaceuticals Inc
|
Revenue
|
442.7m
USD
|
|
Operating Expenses
|
-274.4m
USD
|
|
Operating Income
|
168.3m
USD
|
|
Other Expenses
|
-1.2B
USD
|
|
Net Income
|
-1B
USD
|
Free Cash Flow Analysis
Ironwood Pharmaceuticals Inc
IRWD Profitability Score
Profitability Due Diligence
Ironwood Pharmaceuticals Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Ironwood Pharmaceuticals Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
IRWD Solvency Score
Solvency Due Diligence
Ironwood Pharmaceuticals Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Ironwood Pharmaceuticals Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IRWD Price Targets Summary
Ironwood Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
IRWD
is 18.36 USD
with a low forecast of 14.14 USD and a high forecast of 24.15 USD.
Ownership
IRWD Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
IRWD Price
Ironwood Pharmaceuticals Inc
| Average Annual Return | 0.64% |
| Standard Deviation of Annual Returns | 11.18% |
| Max Drawdown | -51% |
| Market Capitalization | 1.3B USD |
| Shares Outstanding | 156 528 992 |
| Percentage of Shares Shorted | 22.85% |
IRWD News
Last Important Events
Ironwood Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Ironwood Pharmaceuticals Inc
Company Profile
Ironwood Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. The company is headquartered in Boston, Massachusetts and currently employs 219 full-time employees. The company went IPO on 2010-02-03. The company operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company’s products pipeline includes IW-3300, which is a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis, and CNP-104 is a tolerizing immune modifying nanoparticle.
Contact
IPO
Employees
Officers
The intrinsic value of one
IRWD
stock under the Base Case scenario is
12.89
USD.
Compared to the current market price of 8.08 USD,
Ironwood Pharmaceuticals Inc
is
Undervalued by 37%.
You don't have any saved screeners yet
